Biotech

Anatara Lifesciences Ltd (ASX:ANR) Appendix 4E and Financial Report

🕔8/30/2016 8:20:29 AM

Anatara Lifesciences Ltd (ASX:ANR) today released its Appendix 4E for the period ending 30th June 2016.

Read Full Article▸

Regeneus Ltd (ASX:RGS) FY16 Results Presentation

🕔8/24/2016 9:59:03 AM

Regeneus Ltd (ASX:RGS) are pleased to provide a Company Presentation for the Full Year Results for FY16.

Read Full Article▸

Regeneus Ltd (ASX:RGS) FY16 Results Announcement

🕔8/24/2016 9:48:39 AM

Regeneus Ltd (ASX:RGS today reported its 2016 financial results and business update. During the year, the company made significant progress on the development of its portfolio of cell-based therapies for the treatment of osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases for the human and animal health markets.

Read Full Article▸

Regeneus Ltd (ASX:RGS) Appendix 4E and Annual Report 2016

🕔8/24/2016 9:34:59 AM

Regeneus Ltd (ASX:RGS) is an ASX-listed clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases.

Read Full Article▸

Medibio Ltd (ASX:MEB) Breakthrough Validation of Algorithm for Diagnosing Depression Using Independent Clinical Data

🕔8/8/2016 2:10:32 PM

Medibio Ltd (ASX:MEB) is pleased to announce that it has successfully undertaken validation of its depression classification algorithm using retrospective data sourced in partnership with The University of Ottawa. This validation is a significant milestone in the Company's development of a proprietary objective test for the diagnosis of depression.

Read Full Article▸

Regeneus Ltd (ASX:RGS) European Patent to Grant on Stem Cell Secretions Technology for Acne

🕔8/1/2016 10:33:03 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the European Patent Office has decided to grant a patent covering the use of the company's stem cell secretions technology for the topical treatment of acne.

Read Full Article▸

Anatara Lifesciences Ltd (ASX:ANR) Appendix 4C - Quarterly

🕔7/22/2016 8:47:40 AM

Chairman & CEO, Dr Mel Bridges said, "We are extremely pleased to report a positive cash flow for the last quarter, reinforcing a strong balance sheet and cash position. Our cash position allows Anatara the flexibility to execute on moving both our animal and human applications forward to commercial launch," Dr Bridges added.

Read Full Article▸